Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sumitomo Pharmaceuticals America |
---|---|
Information provided by: | Sumitomo Pharmaceuticals America |
ClinicalTrials.gov Identifier: | NCT00044044 |
The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: SM-13496 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 6-Week, Double-Blind, Randomized, Fixed-Dose, Parallel-Group Study of the Efficacy and Safety of Three Dose Levels of SM-13496 Compared to Placebo and Haloperidol in Patients With Schizophrenia Who Are Experiencing an Acute Exacerbation of Symptoms |
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
United States, California | |
Optimum Health Services | |
La Mesa, California, United States, 91942 | |
Sharp Mesa Vista Hospital | |
San Diego, California, United States, 92123 | |
Institute for Psychopharmacology Research | |
Cerritos, California, United States, 90703 | |
Affiliated Research Institute | |
San Diego, California, United States, 92108 | |
United States, District of Columbia | |
Comprehensive Neuroscience. Inc. | |
Washington, District of Columbia, United States, 20016 | |
United States, Florida | |
Comprehensive Neuroscience. Inc. | |
Melbourne, Florida, United States, 32935 | |
Segal Institute for Clinical Research | |
North Miami, Florida, United States, 33161 | |
United States, Georgia | |
Atlanta Center for Medical Research | |
Atlanta, Georgia, United States, 30308 | |
Carman Research | |
Smyrna, Georgia, United States, 30080 | |
United States, Hawaii | |
Hawaii Research Center | |
Honolulu, Hawaii, United States, 96826 | |
United States, Illinois | |
American Medical Research | |
Oakbrook, Illinois, United States, 60523 | |
United States, Maryland | |
Centers for Behavioral Health, LLC | |
Rockville, Maryland, United States, 20850 | |
United States, New Jersey | |
ClinSearch, Inc. | |
Kenilworth, New Jersey, United States, 07033 | |
Comprehensive Clinical Research CNS, PC | |
Clementon, New Jersey, United States, 08021 | |
United States, Pennsylvania | |
Quantum Clinical Services Group | |
Philadelphia, Pennsylvania, United States, 19139 | |
United States, Texas | |
FutureSearch Trials | |
Austin, Texas, United States, 78756 | |
Community Clinical Research | |
Austin, Texas, United States, 78756 | |
University Hills Clinical Research | |
Dallas, Texas, United States, 75235 | |
Claghorn Lesem Research Clinic, Inc. | |
Bellaire, Texas, United States, 77401 | |
United States, Virginia | |
CNS, Inc. | |
Falls Church, Virginia, United States, 22041 | |
United States, Washington | |
Northwest Clinical Research Center | |
Belleview, Washington, United States, 98004 |
Study ID Numbers: | D1050049 |
Study First Received: | August 16, 2002 |
Last Updated: | January 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00044044 |
Health Authority: | United States: Food and Drug Administration |
Schizophrenia |
Haloperidol Schizophrenia Haloperidol decanoate Dopamine |
Mental Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Gastrointestinal Agents Psychotropic Drugs Antiemetics Central Nervous System Depressants |
Dopamine Antagonists Antipsychotic Agents Pharmacologic Actions Autonomic Agents Therapeutic Uses Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |